The First Affiliated Hospital of Xiamen University
🇨🇳China
A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer
Not Applicable
Recruiting
- Conditions
- Positron-Emission Tomography(PET)Prostate CancerTrophoblast Cell Surface Antigen 2
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-12-18
- Target Recruit Count
- 100
- Registration Number
- NCT06696326
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
IMRT Combined with Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
Phase 2
- Conditions
- Nasopharyngeal NeoplasmsElderlyChemotherapy
- Interventions
- Drug: IMRT combined with lobaplatin-based concurrent chemotherapy
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Target Recruit Count
- 32
- Registration Number
- NCT06688175
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
SBRT Combined with Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
Phase 2
- Conditions
- Nasopharyngeal Cancinoma (NPC)SBRTImmunotherapy
- Interventions
- Drug: SBRT combined with Nimotuzumab followed by Tislelizumab
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2024-11-06
- Target Recruit Count
- 20
- Registration Number
- NCT06676722
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients
Phase 1
Recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: D-CMG
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2025-02-24
- Target Recruit Count
- 18
- Registration Number
- NCT06651866
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
Phase 2
Recruiting
- Conditions
- Diffuse Large B-cell LymphomaRelapsed and Refractory
- Interventions
- Drug: Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2025-05-02
- Target Recruit Count
- 22
- Registration Number
- NCT06651853
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors
Phase 2
Recruiting
- Conditions
- Hematological MalignancyLymphocytopenia
- Interventions
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2024-09-04
- Target Recruit Count
- 50
- Registration Number
- NCT06584006
- Locations
- 🇨🇳
Zhijuan Lin, Xiamen, Fujian, China
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 2
Recruiting
- Conditions
- Multiple MyelomaRelapsed/Refractory
- Interventions
- Biological: CAR-T treatment
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-09-03
- Target Recruit Count
- 5
- Registration Number
- NCT06581640
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
Phase 2
Recruiting
- Conditions
- Follicular LymphomaNewly Diagnosed
- Interventions
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-08-14
- Target Recruit Count
- 39
- Registration Number
- NCT06553352
- Locations
- 🇨🇳
Bing Xu, Xiamen, Fujian, China
Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Target Recruit Count
- 50
- Registration Number
- NCT06530004
- Locations
- 🇨🇳
First affiliated hospital of xiamen university, Xiamen, Fujian, China
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
Not Applicable
Recruiting
- Conditions
- Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-07-29
- Target Recruit Count
- 36
- Registration Number
- NCT06478472
- Locations
- 🇨🇳
Bing, Xu, Xiamen, Fujian, China
© Copyright 2025. All Rights Reserved by MedPath